Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma

Yang Hui; Tang Ruihua; Li Jing; Liu Yaxiong; Li Ji; Ye Linjie; Shao Dongyan; Jin Mingliang; Huang Qingsheng; Shi Junling

Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma

Yang Hui
, Tang Ruihua
, Li Jing
, Liu Yaxiong
, Li Ji
, Ye Linjie
, Shao Dongyan
, Jin Mingliang
, Huang Qingsheng
, Shi Junling

School of life sciences

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).

METHODOLOGY: PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.

RESULTS: Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95% CI: 1.00-1.39).

CONCLUSIONS: DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.

Original language	English
Pages (from-to)	1002-1006
Number of pages	5
Journal	Hepato-gastroenterology
Volume	62
Issue number	140
State	Published - 1 Jun 2015

Cite this

@article{d029f572f4034cd0a9014fdeca25f2d6,

title = "Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma",

abstract = "BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).METHODOLOGY: PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95\% confidence interval (CI) was calculated by the Revman 5.0 software.RESULTS: Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95\% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95\% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95\% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95\% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95\% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95\% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95\% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95\% CI: 1.00-1.39).CONCLUSIONS: DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.",

author = "Yang Hui and Tang Ruihua and Li Jing and Liu Yaxiong and Li Ji and Ye Linjie and Shao Dongyan and Jin Mingliang and Huang Qingsheng and Shi Junling",

year = "2015",

month = jun,

day = "1",

language = "英语",

volume = "62",

pages = "1002--1006",

journal = "Hepato-gastroenterology",

issn = "0172-6390",

publisher = "H.G.E. Update Medical Publishing Ltd.",

number = "140",

}

TY - JOUR

T1 - Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma

AU - Hui, Yang

AU - Ruihua, Tang

AU - Jing, Li

AU - Yaxiong, Liu

AU - Ji, Li

AU - Linjie, Ye

AU - Dongyan, Shao

AU - Mingliang, Jin

AU - Qingsheng, Huang

AU - Junling, Shi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).METHODOLOGY: PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.RESULTS: Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95% CI: 1.00-1.39).CONCLUSIONS: DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.

AB - BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).METHODOLOGY: PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.RESULTS: Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95% CI: 1.00-1.39).CONCLUSIONS: DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.

UR - https://www.scopus.com/pages/publications/84979860620

M3 - 文章

C2 - 26902045

AN - SCOPUS:84979860620

SN - 0172-6390

VL - 62

SP - 1002

EP - 1006

JO - Hepato-gastroenterology

JF - Hepato-gastroenterology

IS - 140

ER -

Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma

Abstract

Other files and links

Fingerprint

Cite this